共 50 条
- [31] Integrated Analysis of Bortezomib-Lenalidomide-Dexamethasone vs Bortezomib-Thalidomide-Dexamethasone in Transplant-Eligible Newly Diagnosed MyelomaCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E1 - E2Rosinol, LauraHebraud, BenjaminOriol, AlbertColin, Anne-LaureneTamayo, Rafael RiosHulin, CyrilleBlanchard, Maria JesusCaillot, DenisBalari, Anna SuredaHernandez, Miguel T.Arnulf, BertrandMateos, Maria-VictoriaMacro, MargaretSan-Miguel, JesusBelhadj, KarimLahuerta, Juan-JoseGarelik, M. BrigidBlade, JoanMoreau, PhilippeAttal, Michel
- [32] Preliminary Results of Daratumumab, Cyclophosphamide, Thalidomide and Dexamethasone: A Quadruplet Intensified Treatment for Newly Diagnosed Multiple Myeloma (NDMM) Transplant Eligible (TE) PatientsBLOOD, 2020, 136Crusoe, Edvan De QueirozSalvino, Marco AurelioSilva, Sarah QueirozSantos, Herbert Henrique de MeloSantos, Allan de SouzaAlmeida, Alessandro de M.Vieira, Lucas de OliveiraFonseca, Cleverson AlvesLucas, Larissa FerreiraLeal, JoannaSantos, Mariane MeloSantos, Juliana AndradeAdorno, ElisangelaHungria, Vania T. M.Arruda, Maria da Gloria B.
- [33] Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Improves Depth of Response in Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN Primary AnalysisAMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 : S31 - S31Chari, AjaiVoorhees, Peter M.Kaufman, Jonathan L.Laubach, JacobSborov, Douglas W.Reeves, BrandiRodriguez, CesarSilbermann, RebeccaCosta, Luciano J.Anderson, Larry D., Jr.Nathwani, NityaShah, NinaEfebera, Yvonne A.Costello, CaitlinJakubowiak, AndrzejWildes, Tanya M.Orlowski, Robert Z.Shain, Kenneth H.Cowan, Ander J.Murphy, SeanLutska, YanaPei, HuilingUkropec, JonVermeulen, Jessicade Boer, CarlaHoehn, DanielaLin, Thomas S.Richardson, Paul G.
- [34] Daratumumab (DARA)/Bortezomib/Lenalidomide/Dexamethasone (D-VRd) With D-R Maintenance (Maint) in Transplant-eligible (TE) Newly Diagnosed Myeloma (NDMM): PERSEUS Cytogenetic Risk AnalysisCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S30 - S31Dimopoulos, MeletiosSonneveld, PieterRodriguez-Otero, PaulaHang QuachHo, P. JoyBeksac, MeralHulin, CyrilleAntonioli, ElisabettaLeleu, XavierMangiacavalli, SilviaPerrot, AuroreCavo, MicheleBelotti, AngeloBroijl, AnnemiekGay, FrancescaMina, RobertoNijhof, Inger S.van de Donk, NielsKatodritou, EiriniSitthi-Amorn, Annade Boer, Carla J.Carson, RobinBlade, JoanMoreau, PhilippeBoccadoro, Mario
- [35] Comparative Efficacy and Safety of Bortezomib, Thalidomide, and Dexamethasone (VTd) without and with Daratumumab (D-VTd) from Cassiopeia Versus Vtd from Pethema/GEM in Patients with Newly Diagnosed Multiple Myeloma Using Propensity Score Matching (PSM)BLOOD, 2019, 134Moreau, PhilippeHulin, CyrilleZweegman, SonjaHu, YannanHeeg, BartHashim, Mahmoudde Boer, CarlaVanquickelberghe, VeroniqueKampfenkel, TobiasLam, AnnetteCote, SarahSonneveld, Pieter
- [36] Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance TherapyBLOOD, 2020, 136Kaufman, Jonathan L.Laubach, Jacob P.Sborov, DouglasReeves, BrandiRodriguez, CesarChari, AjaiSilbermann, Rebecca W.Costa, Luciano J.Anderson, Larry D., Jr.Nathwani, NityaShah, NinaEfebera, Yvonne A.Holstein, Sara A.Costello, CaitlinJakubowiak, AndrzejWildes, Tanya M.Orlowski, Robert Z.Shain, Kenneth H.Cowan, Andrew J.Lutska, YanaBobba, PadmaPei, HuilingUkropec, JonVermeulen, JessicaLin, Thomas S.Richardson, Paul G.Voorhees, Peter M.
- [37] Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 24 Months of MaintenanceBLOOD, 2021, 138Kaufman, Jonathan L.Laubach, Jacob P.Sborov, DouglasReeves, BrandiRodriguez, CesarChari, AjaiSilbermann, Rebecca W.Costa, Luciano J.Anderson, Larry D., Jr.Nathwani, NityaShah, NinaEfebera, Yvonne A.Holstein, Sara A.Costello, CaitlinJakubowiak, AndrzejWildes, Tanya M.Orlowski, Robert Z.Shain, Kenneth H.Cowan, Andrew J.Lutska, YanaBobba, PadmaPei, HuilingUkropec, JonVermeulen, JessicaLin, Thomas S.Richardson, Paul G.Voorhees, Peter M.
- [38] Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myelomaFRONTIERS IN ONCOLOGY, 2023, 13Rosinol, LauraHebraud, BenjaminOriol, AlbertColin, Anne-LaureneTamayo, Rafael RiosHulin, CyrilleBlanchard, Maria JesusCaillot, DenisSureda, AnnaHernandez, Miguel TeodoroArnulf, BertrandMateos, Maria-VictoriaMacro, MargaretSan-Miguel, JesusBelhadj, KarimLahuerta, Juan JoseGarelik, M. BrigidBlade, JoanMoreau, Philippe
- [39] Daratumumab (Dara), Cyclophosphamide, Thalidomide and Dexamethasone: a quadruplet intensified treatment for transplant eligible newly diagnosed Multiple Myeloma (TE NDMM) patients final resultsCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S130 - S130Crusoe, EdvanSantos, JulianaLeal, JOannaSantos, HerbertSantos, AllanAlmeida, AlessandroSantos, MarianeLucas, LarissaQueiroz, SarahFonseca, CleversonAdorno, ElisangelaVieira, LucasHungria, VaniaSalvino, MarcoArruda, Maria da Gloria
- [40] An End-of-Study Subgroup Analysis of Black Patients from the Phase 2 Griffin Study of Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM)BLOOD, 2022, 140 : 10154 - 10156Nooka, Ajay K.Kaufman, Jonathan L.Rodriguez, CesarJakubowiak, AndrzejEfebera, Yvonne A.Reeves, BrandiWildes, Tanya M.Holstein, Sarah A.Anderson, Larry D., Jr.Badros, Ashraf Z.Shune, Leyla O.Chari, AjaiPei, HuilingCortoos, AnnelorePatel, SharmilaLin, Thomas S.Richardson, Paul G.Usmani, SaadVoorhees, Peter M.